ENROLLING | RESTORE CFTR FUNCTION
Phase 2 study of VX-440 combination drug in people with cystic fibrosis ›
DESCRIPTION: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661).
AGE: 12 Years and Older
MUTATION: Two Copies F508del or One Copy F508del
FEV1% PREDICTED: 40 to 90%
NUMBER OF VISITS: 11
LENGTH OF PARTICIPATION: 57 days
https://clinicaltrials.gov/ct2/show/NCT02951182?term=tezacaftor&rank=1
ENROLLING | RESTORE CFTR FUNCTION
Phase 2 study of VX-152 combination drug in people with cystic fibrosis ›
DESCRIPTION: This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).
AGE: 18 Years and Older
MUTATION: Two Copies F508del or One Copy F508del
FEV1% PREDICTED: 40 to 90%
NUMBER OF VISITS: 10
LENGTH OF PARTICIPATION: 16 weeks
https://clinicaltrials.gov/ct2/show/NCT02951195?term=tezacaftor&rank=2
Phase 2 study of VX-440 combination drug in people with cystic fibrosis ›
DESCRIPTION: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-440 in combination with ivacaftor and/or tezacaftor (VX-661).
AGE: 12 Years and Older
MUTATION: Two Copies F508del or One Copy F508del
FEV1% PREDICTED: 40 to 90%
NUMBER OF VISITS: 11
LENGTH OF PARTICIPATION: 57 days
https://clinicaltrials.gov/ct2/show/NCT02951182?term=tezacaftor&rank=1
ENROLLING | RESTORE CFTR FUNCTION
Phase 2 study of VX-152 combination drug in people with cystic fibrosis ›
DESCRIPTION: This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).
AGE: 18 Years and Older
MUTATION: Two Copies F508del or One Copy F508del
FEV1% PREDICTED: 40 to 90%
NUMBER OF VISITS: 10
LENGTH OF PARTICIPATION: 16 weeks
https://clinicaltrials.gov/ct2/show/NCT02951195?term=tezacaftor&rank=2
Last edited:
